In the past 10 years, there has been a lot of enthusiasm surrounding the use of serum
hepatitis B surface antigen (HBsAg) quantification to predict disease activity and monitor …

Background: Direct-acting antiviral agents (DAAs) are used increasingly to treat hepatitis C
virus (HCV) infection. Reports were published recently on hepatitis B virus (HBV) …

Hepatitis due to reactivation of hepatitis B virus (HBV) has been reported in patients treated
with direct-acting antiviral (DAA) agents for chronic hepatitis C virus infection. We performed …

There is an increased awareness of hepatitis B (HBV) reactivation in chronic hepatitis C
(CHC) patients coinfected with HBV treated with pan‐oral direct‐acting antiviral agents …

Hepatocellular carcinoma (HCC) is the second cause of death due to malignancy in the
world, following lung cancer. The geographic distribution of this disease accompanies its …

Use of direct-acting antiviral drugs (DAAs) greatly improves management of adults infected
with hepatitis C virus (HCV) whether patients are treatment-naive or unsuccessfully pre …

Reactivation of hepatitis B virus (HBV) has been reported in hepatitis C virus–infected
individuals receiving direct‐acting antiviral (DAA) therapy. The overall risk among patients …

Background & Aims There have been reports of reactivation of hepatitis B virus (HBV)
infection during treatment of hepatitis C virus (HCV) infection with direct-acting antiviral …

Summary Background Hepatitis B virus (HBV)/hepatitis C virus (HCV) confection has been
rarely studied in nonasian series. Aim To compare the characteristics of HBV/HCV …

The Drafting Committee for Hepatitis Management Guidelines established by the Japan
Society of Hepatology published the first version of the Guidelines for the Management of …